US Patent

US11666573 — Dosage regimen of paliperidone palmitate extended-release injectable suspension

Method of Use · Assigned to Geneora Pharma Shijiazhuang Co Ltd · Expires 2039-09-24 · 13y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects simplified dosing regimens for administering paliperidone palmitate to treat schizophrenia or schizoaffective disorders.

USPTO Abstract

Provided herein are simplified dosing regimens for administering paliperidone palmitate to a patient in need of treatment of schizophrenia or schizoaffective disorders.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3968 — Invega Sustenna
U-3969 — Invega Sustenna
U-3969 — Invega Sustenna
U-3969 — Invega Sustenna
U-3969 — Invega Sustenna
U-3969 — Invega Sustenna

Patent Metadata

Patent number
US11666573
Jurisdiction
US
Classification
Method of Use
Expires
2039-09-24
Drug substance claim
No
Drug product claim
No
Assignee
Geneora Pharma Shijiazhuang Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.